| Post | Subject | | |
#218583
0
|
MOR sells 9.55M ADSs@$25.04 in Nasdaq IPO:
|
DewDiligence
| 04/18/18 06:51:32 PM |
|
#218574
0
|
GNCA highlights neoadjuvant-selection process:
|
DewDiligence
| 04/18/18 04:29:56 PM |
|
#218567
0
|
ARNA- Good interview by Amit Munshi on
|
Mufaso
| 04/18/18 10:24:51 AM |
|
#218561
0
|
BMY: I think the logic behind that tweet
|
JohnWayne
| 04/17/18 10:15:06 PM |
|
#218539
0
|
ASMB - 4/12/18 CC notes
|
mcbio
| 04/16/18 09:20:48 PM |
|
#218435
0
|
RVNC does have the Botox cell line, as
|
DewDiligence
| 04/11/18 05:26:29 PM |
|
#218594
0
|
NBRV Sheff made some bullish comments on the
|
bUrRpPPP!
| 04/19/18 05:45:45 AM |
|
#218593
0
|
CCP just shut down an Android app downloaded
|
NY1972
| 04/19/18 12:06:11 AM |
|
#218592
0
|
CLSD - it appears, if I am reading
|
Bickema
| 04/18/18 11:18:45 PM |
|
#218591
0
|
Ok, I see you were talking about OS
|
jq1234
| 04/18/18 10:58:53 PM |
|
#218590
0
|
BMY:
“One minor correction to your post, OS secondary
|
JohnWayne
| 04/18/18 10:35:24 PM |
|
#218589
0
|
ASMB - What is the real reason for
|
mcbio
| 04/18/18 10:33:37 PM |
|
#218588
0
|
Re: Aprea/(KDEV.ST) - Looks to me like it's
|
mcbio
| 04/18/18 09:22:54 PM |
|
#218587
0
|
CLSD - Anyone looked into or have an
|
Bickema
| 04/18/18 09:12:45 PM |
|
#218586
0
|
FDA approves AZN’s Tagrisso for first-line metastatic or
|
DewDiligence
| 04/18/18 07:57:29 PM |
|
#218585
0
|
ASMB—The phase-2a trial design is ok, but I
|
DewDiligence
| 04/18/18 07:21:22 PM |
|
#218584
0
|
Re: ASMB
|
mcbio
| 04/18/18 07:07:10 PM |
|
#218583
0
|
MOR sells 9.55M ADSs@$25.04 in Nasdaq IPO:
|
DewDiligence
| 04/18/18 06:51:32 PM |
|
#218582
0
|
Re: BMY I-O counterpoint
|
DewDiligence
| 04/18/18 05:18:51 PM |
|
#218581
0
|
Other 1st line ph3 trials mainly from melanoma
|
jq1234
| 04/18/18 05:13:46 PM |
|
#218580
0
|
I don’t think the market is pricing nivolumab
|
DewDiligence
| 04/18/18 05:09:04 PM |
|
#218579
0
|
CheckMate-227:
Agreed completely. If much higher percentage of randomized
|
jq1234
| 04/18/18 05:00:33 PM |
|
#218577
0
|
VTVT—>4-bagger off last week’s low, but still -33%
|
DewDiligence
| 04/18/18 04:49:25 PM |
|
#218576
0
|
Opdivo BLA for monotherapy in third-line SCLC has
|
DewDiligence
| 04/18/18 04:42:18 PM |
|
#218575
0
|
Re: ASMB CC First P2a study designed
|
DewDiligence
| 04/18/18 04:36:11 PM |
|
#218574
0
|
GNCA highlights neoadjuvant-selection process:
|
DewDiligence
| 04/18/18 04:29:56 PM |
|
#218573
0
|
I’ve seen similar hedged language by other companies,
|
DewDiligence
| 04/18/18 04:25:27 PM |
|
#218572
0
|
CATB closes +13% from yesterday’s AH low upon
|
Titan V
| 04/18/18 04:18:16 PM |
|
#218571
0
|
Looks to me like it's likely real. But
|
biomaven0
| 04/18/18 03:07:16 PM |
|
#218570
0
|
Do you attribute the increased efficacy, OS, of
|
north40000
| 04/18/18 01:47:37 PM |
|
#218569
0
|
QBL News; MMJ Solution on addiction!!Up 19% weekly.
|
Alexulf
| 04/18/18 11:59:48 AM |
|
#218568
0
|
Agree. I listened to the interview as well.
|
kris_kade
| 04/18/18 11:12:22 AM |
|
#218567
0
|
ARNA- Good interview by Amit Munshi on
|
Mufaso
| 04/18/18 10:24:51 AM |
|
#218566
0
|
BLCM sells 9.20M* shares @$7.50—a 16% discount to
|
DewDiligence
| 04/18/18 10:21:16 AM |
|
#218565
0
|
“Those are the verbatim phrases used by AGN's
|
biotech_researcher
| 04/18/18 09:33:32 AM |
|
#218564
0
|
Barclays analyst Douglas Tsao says that while he'd
|
DewDiligence
| 04/18/18 09:21:05 AM |
|
#218563
0
|
BMY
dough (@tgtxdough)
4/18/18, 7:42 AM
BMO $BMY key growth driver
|
biotech_researcher
| 04/18/18 08:21:05 AM |
|
#218562
0
|
Barclays sees 'significant challenges' for Botox biosimilar
|
jbog
| 04/18/18 07:30:33 AM |
|
#218561
0
|
BMY: I think the logic behind that tweet
|
JohnWayne
| 04/17/18 10:15:06 PM |
|
#218560
0
|
4,000,000 Reasons to Back China Biotech
|
jbog
| 04/17/18 07:46:40 PM |
|
#218559
0
|
FDA approves RARE’s Crysveta for X–linked hypophosphatemia:
|
DewDiligence
| 04/17/18 06:16:19 PM |
|
#218558
0
|
I don't follow CATB closely enough to address
|
DewDiligence
| 04/17/18 04:56:04 PM |
|
#218557
0
|
Any thoughts on CATB in general Dew? They
|
Titan V
| 04/17/18 04:49:22 PM |
|
#218556
0
|
CATB—(-6%/AH)—lays off 42% of workforce:
|
DewDiligence
| 04/17/18 04:36:52 PM |
|
#218555
0
|
Dumbing down in NYT article on statins:
|
DewDiligence
| 04/17/18 02:32:53 PM |
|
#218554
0
|
Vaccibody—>a neoantigen-vaccine company I hadn’t heard of:
|
DewDiligence
| 04/17/18 02:29:08 PM |
|
#218553
0
|
Re: BMY's prospects in first-line NSCLC
|
DewDiligence
| 04/17/18 02:18:58 PM |
|
#218552
0
|
FDA approves RIGL’s Tavalisse (fostamatinib) for second-line ITP;
|
DewDiligence
| 04/17/18 02:09:42 PM |
|
#218551
0
|
Anti-PD-1 response restored after introduction of diverse microbiome
|
biocqr
| 04/17/18 12:36:47 PM |
|
#218550
0
|
Findings showed that the KEYTRUDA-pemetrexed-platinum chemotherapy combin
|
vinmantoo
| 04/17/18 12:30:28 PM |
|
#218548
0
|
CLVS raises $460M* in common stock and convertible debt:
|
DewDiligence
| 04/17/18 11:27:27 AM |
|
#218547
0
|
RVNC—I expect an update at the Investor Day
|
DewDiligence
| 04/17/18 11:14:29 AM |
|
#218546
0
|
Revance -- Plantar Fasciitis
|
mouton29
| 04/17/18 10:49:38 AM |
|
#218545
0
|
Re: GWPH
|
haysaw
| 04/17/18 09:48:13 AM |
|
#218544
0
|
This is an odd partnership insofar as BMY
|
biopharm
| 04/17/18 09:23:33 AM |
|
#218543
0
|
ARQL licenses Derazantinib to Basilea, a Swiss company
|
bladerunner1717
| 04/17/18 09:19:33 AM |
| Post | Subject | | |